Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy
Keqiang Zhang, Ching Ouyang, Jonathan Castillo, Jinhui Wang, Walter Tsark, Yuanyuan Gao, Wendong Li, Minxiao Yang, Aimin Li, Britney Oeung, Colt Egelston, Jun Wu, Mahima Raul, Leonidas Arvanitis, Crystal Marconett, Dan J Raz · 2026
Read Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy by Keqiang Zhang, Ching Ouyang, Jonathan Castillo, Jinhui Wang, Walter Tsark, Yuanyuan Gao, Wendong Li, Minxiao Yang, Aimin Li, Britney Oeung, Colt Egelston, Jun Wu, Mahima Raul, Leonidas Arvanitis, Crystal Marconett, Dan J Raz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13549226.txt.
Description
RationaleUbiquitin-specific peptidase 22 (USP22), a deubiquitinase and component of the “Death-from-Cancer” 11-gene signature, is overexpressed in multiple malignancies and linked to recurrence, therapy resistance, and poor prognosis. Its role in KRAS/p53-driven lung cancer and the response to immune checkpoint inhibitors (ICIs) remains poorly defined. Here, we investigated USP22 as a potential therapeutic target in KRAS/p53-driven lung cancer.
Catalog record
| CREATOR | Keqiang Zhang, Ching Ouyang, Jonathan Castillo, Jinhui Wang, Walter Tsark, Yuanyuan Gao, Wendong Li, Minxiao Yang, Aimin Li, Britney Oeung, Colt Egelston, Jun Wu, Mahima Raul, Leonidas Arvanitis, Crystal Marconett, Dan J Raz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |